 Richard Duke
Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Membrane Glycoproteins | 17 | 2004 | 430 | 0.940 |
Why?
| | Apoptosis | 21 | 2012 | 2363 | 0.850 |
Why?
| | Fas Ligand Protein | 16 | 2012 | 57 | 0.730 |
Why?
| | T-Lymphocytes, Cytotoxic | 9 | 2006 | 154 | 0.710 |
Why?
| | Cytotoxicity, Immunologic | 11 | 2004 | 195 | 0.480 |
Why?
| | Genetic Therapy | 4 | 2012 | 257 | 0.430 |
Why?
| | Killer Cells, Natural | 3 | 2004 | 380 | 0.370 |
Why?
| | fas Receptor | 8 | 2004 | 91 | 0.360 |
Why?
| | Bone Neoplasms | 1 | 2012 | 194 | 0.350 |
Why?
| | Immunotherapy | 5 | 2010 | 474 | 0.320 |
Why?
| | Chromatin | 3 | 2004 | 428 | 0.320 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2006 | 127 | 0.320 |
Why?
| | T-Lymphocytes | 11 | 2004 | 1737 | 0.290 |
Why?
| | Viral Hepatitis Vaccines | 1 | 2006 | 1 | 0.280 |
Why?
| | Viral Core Proteins | 1 | 2006 | 20 | 0.280 |
Why?
| | Saccharomyces cerevisiae | 4 | 2010 | 476 | 0.270 |
Why?
| | Viral Nonstructural Proteins | 1 | 2006 | 54 | 0.260 |
Why?
| | Hepacivirus | 1 | 2006 | 229 | 0.240 |
Why?
| | Transplantation Immunology | 2 | 1999 | 30 | 0.240 |
Why?
| | Recombinant Fusion Proteins | 2 | 2006 | 616 | 0.230 |
Why?
| | Biological Assay | 1 | 2004 | 112 | 0.220 |
Why?
| | Adenoviridae | 3 | 2004 | 184 | 0.200 |
Why?
| | Graft Rejection | 3 | 2002 | 513 | 0.200 |
Why?
| | Animals | 38 | 2012 | 31709 | 0.180 |
Why?
| | Tumor Cells, Cultured | 13 | 2003 | 850 | 0.180 |
Why?
| | Prostatic Neoplasms | 4 | 1999 | 921 | 0.170 |
Why?
| | Testis | 2 | 1999 | 133 | 0.160 |
Why?
| | Mice | 27 | 2010 | 14872 | 0.160 |
Why?
| | Mice, Inbred BALB C | 8 | 2010 | 1144 | 0.150 |
Why?
| | Thymus Gland | 1 | 1999 | 296 | 0.150 |
Why?
| | Bacterial Toxins | 2 | 1996 | 103 | 0.140 |
Why?
| | Viral Proteins | 1 | 1999 | 281 | 0.140 |
Why?
| | DNA Damage | 2 | 1989 | 351 | 0.140 |
Why?
| | Endonucleases | 4 | 1988 | 30 | 0.130 |
Why?
| | DNA | 7 | 1994 | 1352 | 0.120 |
Why?
| | Melitten | 1 | 1994 | 3 | 0.110 |
Why?
| | Valinomycin | 1 | 1994 | 4 | 0.110 |
Why?
| | Calcimycin | 1 | 1994 | 47 | 0.110 |
Why?
| | Hemolysin Proteins | 1 | 1994 | 31 | 0.110 |
Why?
| | Dogs | 2 | 2012 | 334 | 0.110 |
Why?
| | Lymphocyte Activation | 6 | 2004 | 1037 | 0.100 |
Why?
| | Interleukin-2 | 5 | 1998 | 413 | 0.100 |
Why?
| | Transfection | 3 | 1999 | 866 | 0.100 |
Why?
| | Necrosis | 2 | 2012 | 211 | 0.100 |
Why?
| | Vaccines, Synthetic | 3 | 2010 | 124 | 0.100 |
Why?
| | Osteosarcoma | 1 | 2012 | 67 | 0.100 |
Why?
| | Melanoma | 3 | 2003 | 620 | 0.090 |
Why?
| | Calcium | 3 | 1994 | 1108 | 0.090 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2010 | 61 | 0.090 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 95 | 0.080 |
Why?
| | Cancer Vaccines | 1 | 2010 | 137 | 0.080 |
Why?
| | AIDS Vaccines | 2 | 2001 | 41 | 0.080 |
Why?
| | Major Histocompatibility Complex | 1 | 1989 | 217 | 0.080 |
Why?
| | Cytoplasmic Granules | 1 | 1988 | 82 | 0.080 |
Why?
| | Cell Line | 7 | 1998 | 2637 | 0.070 |
Why?
| | Mice, Inbred C57BL | 6 | 2010 | 4694 | 0.070 |
Why?
| | Neoplasms, Experimental | 2 | 2004 | 151 | 0.070 |
Why?
| | Ionomycin | 2 | 2004 | 24 | 0.070 |
Why?
| | Lymphocyte Depletion | 1 | 1986 | 116 | 0.060 |
Why?
| | Autoimmunity | 2 | 2004 | 813 | 0.060 |
Why?
| | Mice, Inbred Strains | 4 | 2004 | 396 | 0.060 |
Why?
| | HeLa Cells | 1 | 2006 | 562 | 0.060 |
Why?
| | Yeasts | 1 | 2005 | 49 | 0.060 |
Why?
| | Lymphocytes | 4 | 1998 | 330 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2002 | 959 | 0.060 |
Why?
| | Ionophores | 1 | 2004 | 22 | 0.060 |
Why?
| | Egtazic Acid | 1 | 2004 | 44 | 0.060 |
Why?
| | DNA Fragmentation | 1 | 2004 | 47 | 0.060 |
Why?
| | Hepatitis C | 1 | 2006 | 219 | 0.060 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2004 | 153 | 0.060 |
Why?
| | In Situ Nick-End Labeling | 1 | 2004 | 119 | 0.060 |
Why?
| | Molecular Sequence Data | 5 | 2010 | 2785 | 0.060 |
Why?
| | Chelating Agents | 1 | 2004 | 65 | 0.060 |
Why?
| | Membrane Proteins | 1 | 1989 | 1019 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2005 | 222 | 0.050 |
Why?
| | Cell Survival | 4 | 1991 | 1021 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2004 | 228 | 0.050 |
Why?
| | Ultraviolet Rays | 2 | 2004 | 363 | 0.050 |
Why?
| | Dog Diseases | 1 | 2003 | 41 | 0.050 |
Why?
| | Cell Division | 3 | 2002 | 758 | 0.050 |
Why?
| | Glucocorticoids | 3 | 1999 | 532 | 0.050 |
Why?
| | Arthritis, Experimental | 1 | 2004 | 130 | 0.050 |
Why?
| | Microscopy | 1 | 2004 | 125 | 0.050 |
Why?
| | Cytokines | 3 | 2006 | 1841 | 0.050 |
Why?
| | Genes, ras | 1 | 2002 | 91 | 0.050 |
Why?
| | Fluorescent Dyes | 1 | 2004 | 301 | 0.050 |
Why?
| | Immunity, Cellular | 2 | 2001 | 248 | 0.050 |
Why?
| | Perforin | 2 | 1992 | 18 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2002 | 377 | 0.050 |
Why?
| | Pore Forming Cytotoxic Proteins | 2 | 1992 | 15 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2004 | 1143 | 0.050 |
Why?
| | Humans | 22 | 2006 | 114705 | 0.050 |
Why?
| | Lung Neoplasms | 3 | 2004 | 2177 | 0.040 |
Why?
| | Flow Cytometry | 3 | 1999 | 1083 | 0.040 |
Why?
| | B-Lymphocytes | 2 | 1996 | 766 | 0.040 |
Why?
| | HIV-1 | 2 | 1996 | 768 | 0.040 |
Why?
| | DNA Primers | 3 | 1996 | 510 | 0.040 |
Why?
| | Antigens | 2 | 1992 | 318 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2006 | 2711 | 0.040 |
Why?
| | Base Sequence | 4 | 1996 | 2114 | 0.040 |
Why?
| | Lymphoma | 3 | 1998 | 177 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2002 | 388 | 0.040 |
Why?
| | MAP Kinase Kinase Kinase 1 | 1 | 1999 | 14 | 0.040 |
Why?
| | Immediate-Early Proteins | 1 | 1999 | 52 | 0.040 |
Why?
| | Phosphoprotein Phosphatases | 1 | 1999 | 64 | 0.040 |
Why?
| | Poxviridae | 1 | 1999 | 2 | 0.040 |
Why?
| | Spheroids, Cellular | 1 | 1999 | 56 | 0.040 |
Why?
| | Cell Transplantation | 1 | 1999 | 36 | 0.040 |
Why?
| | Serpins | 1 | 1999 | 25 | 0.040 |
Why?
| | I-kappa B Proteins | 1 | 1999 | 79 | 0.040 |
Why?
| | Myocarditis | 1 | 2000 | 93 | 0.040 |
Why?
| | Mice, Nude | 2 | 1999 | 630 | 0.040 |
Why?
| | Transplantation, Heterologous | 1 | 1999 | 181 | 0.040 |
Why?
| | Male | 12 | 2004 | 55607 | 0.040 |
Why?
| | Transduction, Genetic | 1 | 1999 | 113 | 0.040 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 1999 | 147 | 0.040 |
Why?
| | Receptors, Virus | 1 | 1998 | 75 | 0.040 |
Why?
| | Depsipeptides | 1 | 1998 | 13 | 0.040 |
Why?
| | Cell Adhesion | 1 | 1999 | 432 | 0.040 |
Why?
| | Cell Nucleus | 3 | 1994 | 554 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2001 | 435 | 0.040 |
Why?
| | Neoplasms | 2 | 2005 | 2097 | 0.040 |
Why?
| | Toxoplasma | 1 | 1998 | 31 | 0.040 |
Why?
| | Immunoglobulin M | 2 | 1998 | 246 | 0.040 |
Why?
| | Cell Death | 2 | 2004 | 323 | 0.030 |
Why?
| | HIV Envelope Protein gp160 | 1 | 1996 | 7 | 0.030 |
Why?
| | Molecular Weight | 2 | 1989 | 331 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 1996 | 192 | 0.030 |
Why?
| | Superantigens | 1 | 1996 | 69 | 0.030 |
Why?
| | Enterotoxins | 1 | 1996 | 88 | 0.030 |
Why?
| | Cerebrovascular Disorders | 1 | 1996 | 82 | 0.030 |
Why?
| | Rats | 2 | 1999 | 4958 | 0.030 |
Why?
| | Cell Cycle | 1 | 1998 | 542 | 0.030 |
Why?
| | Serine Endopeptidases | 1 | 1996 | 102 | 0.030 |
Why?
| | Tissue Transplantation | 1 | 1995 | 11 | 0.030 |
Why?
| | Sertoli Cells | 1 | 1995 | 21 | 0.030 |
Why?
| | Endodeoxyribonucleases | 2 | 1986 | 59 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 1999 | 551 | 0.030 |
Why?
| | RNA, Messenger | 3 | 2002 | 2553 | 0.030 |
Why?
| | HIV Envelope Protein gp120 | 1 | 1995 | 56 | 0.030 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 1995 | 17 | 0.030 |
Why?
| | NF-kappa B | 1 | 1999 | 641 | 0.030 |
Why?
| | Alopecia Areata | 1 | 1995 | 9 | 0.030 |
Why?
| | Skin Neoplasms | 1 | 2002 | 756 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1996 | 217 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2001 | 797 | 0.030 |
Why?
| | Hair | 1 | 1995 | 65 | 0.030 |
Why?
| | Cells, Cultured | 4 | 2001 | 3886 | 0.030 |
Why?
| | Receptors, Complement | 1 | 1995 | 111 | 0.030 |
Why?
| | Virus Diseases | 1 | 1996 | 195 | 0.030 |
Why?
| | Salmonella typhimurium | 1 | 1995 | 164 | 0.030 |
Why?
| | Mitochondria | 1 | 1999 | 747 | 0.030 |
Why?
| | Heart Diseases | 1 | 1996 | 331 | 0.030 |
Why?
| | Immunization | 1 | 1995 | 397 | 0.030 |
Why?
| | Spleen | 1 | 1995 | 487 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 2004 | 1230 | 0.030 |
Why?
| | Peptides | 1 | 1998 | 848 | 0.030 |
Why?
| | Fetus | 1 | 1996 | 700 | 0.030 |
Why?
| | Mice, Transgenic | 3 | 2002 | 1950 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 1998 | 795 | 0.020 |
Why?
| | Protein Biosynthesis | 2 | 1984 | 387 | 0.020 |
Why?
| | Mice, Inbred DBA | 2 | 2004 | 174 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 1982 | 0.020 |
Why?
| | Zinc | 2 | 1984 | 260 | 0.020 |
Why?
| | Skin | 1 | 1995 | 655 | 0.020 |
Why?
| | Cardiomegaly | 2 | 2002 | 157 | 0.020 |
Why?
| | Leukemia, Experimental | 1 | 2010 | 27 | 0.020 |
Why?
| | Genes, MHC Class I | 1 | 2010 | 32 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1989 | 1016 | 0.020 |
Why?
| | Enzyme Activation | 2 | 1999 | 785 | 0.020 |
Why?
| | Terminology as Topic | 1 | 1991 | 187 | 0.020 |
Why?
| | Dexamethasone | 2 | 1999 | 317 | 0.020 |
Why?
| | Lectins | 1 | 1989 | 42 | 0.020 |
Why?
| | Mast-Cell Sarcoma | 1 | 1988 | 4 | 0.020 |
Why?
| | Mice, Inbred CBA | 1 | 1988 | 49 | 0.020 |
Why?
| | Kidney | 1 | 1995 | 1188 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2010 | 620 | 0.020 |
Why?
| | Species Specificity | 1 | 1989 | 542 | 0.020 |
Why?
| | Oligosaccharides | 1 | 1988 | 46 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 796 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1991 | 615 | 0.020 |
Why?
| | Cell Separation | 1 | 1988 | 291 | 0.020 |
Why?
| | Histocompatibility Antigens | 1 | 1988 | 98 | 0.020 |
Why?
| | Magnesium | 2 | 1985 | 145 | 0.020 |
Why?
| | Promoter Regions, Genetic | 2 | 2002 | 1131 | 0.020 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1986 | 41 | 0.020 |
Why?
| | Models, Molecular | 1 | 2010 | 1369 | 0.020 |
Why?
| | Urethane | 1 | 2004 | 41 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1984 | 25 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 2004 | 157 | 0.010 |
Why?
| | Adoptive Transfer | 1 | 2004 | 195 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1984 | 193 | 0.010 |
Why?
| | Antibodies | 2 | 1996 | 371 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1996 | 993 | 0.010 |
Why?
| | Corticosterone | 1 | 1984 | 211 | 0.010 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1988 | 577 | 0.010 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2002 | 20 | 0.010 |
Why?
| | Adenoma | 1 | 2004 | 189 | 0.010 |
Why?
| | HIV Infections | 1 | 1995 | 2469 | 0.010 |
Why?
| | Myosin Heavy Chains | 1 | 2002 | 177 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 923 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2003 | 493 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 355 | 0.010 |
Why?
| | Cell Size | 1 | 2000 | 80 | 0.010 |
Why?
| | Kinetics | 1 | 1983 | 1551 | 0.010 |
Why?
| | Down-Regulation | 1 | 2002 | 594 | 0.010 |
Why?
| | Transcription, Genetic | 2 | 1996 | 1313 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 10 | 1 | 1999 | 3 | 0.010 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 1999 | 3 | 0.010 |
Why?
| | Metallothionein | 1 | 1999 | 24 | 0.010 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 1999 | 28 | 0.010 |
Why?
| | Protein Phosphatase 1 | 1 | 1999 | 29 | 0.010 |
Why?
| | Phagocytosis | 2 | 1992 | 350 | 0.010 |
Why?
| | Gene Dosage | 1 | 2000 | 129 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1999 | 27 | 0.010 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 1999 | 52 | 0.010 |
Why?
| | Mitogens | 1 | 1999 | 58 | 0.010 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 1999 | 68 | 0.010 |
Why?
| | Hybridomas | 1 | 1999 | 230 | 0.010 |
Why?
| | Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 1998 | 7 | 0.010 |
Why?
| | Membrane Potentials | 1 | 1999 | 248 | 0.010 |
Why?
| | Thymus Neoplasms | 1 | 1998 | 21 | 0.010 |
Why?
| | Thymoma | 1 | 1998 | 30 | 0.010 |
Why?
| | CD3 Complex | 1 | 1998 | 92 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2002 | 695 | 0.010 |
Why?
| | Caspases | 1 | 1999 | 245 | 0.010 |
Why?
| | Cycloheximide | 1 | 1998 | 54 | 0.010 |
Why?
| | Dactinomycin | 1 | 1998 | 25 | 0.010 |
Why?
| | Androgens | 1 | 1999 | 167 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 1999 | 278 | 0.010 |
Why?
| | Gamma Rays | 1 | 1998 | 48 | 0.010 |
Why?
| | Myocardium | 1 | 2002 | 913 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1998 | 239 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2000 | 448 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1998 | 289 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 1998 | 397 | 0.010 |
Why?
| | Ligands | 1 | 1998 | 562 | 0.010 |
Why?
| | Proprotein Convertase 5 | 1 | 1996 | 1 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 1998 | 523 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1999 | 395 | 0.010 |
Why?
| | Models, Immunological | 1 | 1996 | 92 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1996 | 256 | 0.010 |
Why?
| | Signal Transduction | 2 | 1998 | 4516 | 0.010 |
Why?
| | HIV Antibodies | 1 | 1995 | 49 | 0.010 |
Why?
| | Multigene Family | 1 | 1996 | 190 | 0.010 |
Why?
| | Exudates and Transudates | 1 | 1995 | 12 | 0.010 |
Why?
| | Adult | 1 | 1996 | 30553 | 0.010 |
Why?
| | Receptor Aggregation | 1 | 1995 | 8 | 0.010 |
Why?
| | Peritoneum | 1 | 1995 | 36 | 0.010 |
Why?
| | Proto-Oncogenes | 1 | 1995 | 26 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1996 | 522 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1995 | 119 | 0.010 |
Why?
| | Rabbits | 1 | 1996 | 733 | 0.010 |
Why?
| | Antibody Formation | 1 | 1996 | 266 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 1998 | 1167 | 0.010 |
Why?
| | Plasmids | 1 | 1995 | 343 | 0.010 |
Why?
| | Reference Values | 1 | 1996 | 743 | 0.010 |
Why?
| | Mammals | 1 | 1996 | 244 | 0.010 |
Why?
| | Epidermis | 1 | 1995 | 149 | 0.010 |
Why?
| | Gene Expression | 1 | 1999 | 1421 | 0.010 |
Why?
| | Mutation | 1 | 2004 | 3346 | 0.010 |
Why?
| | Keratinocytes | 1 | 1995 | 216 | 0.010 |
Why?
| | Administration, Oral | 1 | 1995 | 728 | 0.010 |
Why?
| | Age Factors | 1 | 2000 | 2894 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1996 | 719 | 0.010 |
Why?
| | Staphylococcus aureus | 1 | 1996 | 389 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 1999 | 1314 | 0.010 |
Why?
| | Immunity, Innate | 1 | 1998 | 720 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1996 | 770 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 1842 | 0.010 |
Why?
| | Phenotype | 1 | 1999 | 2797 | 0.010 |
Why?
| | CD4 Antigens | 1 | 1991 | 123 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 1995 | 532 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1481 | 0.000 |
Why?
| | Clone Cells | 1 | 1988 | 247 | 0.000 |
Why?
| | Neoplasm Transplantation | 1 | 1988 | 228 | 0.000 |
Why?
| | Interphase | 1 | 1985 | 32 | 0.000 |
Why?
| | Female | 2 | 2004 | 59521 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1988 | 1264 | 0.000 |
Why?
|
|
Duke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|